SAB Biotherapeutics Inc. (SABS)
1.64
0.05 (3.14%)
At close: Mar 21, 2025, 3:59 PM
3.14% (1D)
| Bid | 1.41 |
| Market Cap | 15.14M |
| Revenue (ttm) | 1.51M |
| Net Income (ttm) | -45.42M |
| EPS (ttm) | -6.3 |
| PE Ratio (ttm) | -0.26 |
| Forward PE | -0.44 |
| Analyst | Buy |
| Ask | 1.94 |
| Volume | 37,248 |
| Avg. Volume (20D) | 119,015 |
| Open | 1.64 |
| Previous Close | 1.59 |
| Day's Range | 1.53 - 1.72 |
| 52-Week Range | 1.45 - 5.01 |
| Beta | 0.45 |
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ tran...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 57
Stock Exchange NASDAQ
Ticker Symbol SABS
Analyst Forecast
According to 5 analyst ratings, the average rating for SABS stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 479.27% from the latest price.
Stock ForecastsNext Earnings Release
SAB Biotherapeutics Inc. is scheduled to release its earnings on Apr 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+17.06%
SAB Biotherapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
7 months ago
-12.92%
SAB Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.
